Going big: Biotech vets blast off with Arrakis on a new journey of RNA exploration
Michael Gilman and an experienced band of biotech vets are busting out of stealth mode today with a startup that marks the serial entrepreneur’s third launch in 10 years. And he’s coming out in style, with a $38 million A round led by Canaan Partners.
After literally stumbling across the company while it was still in the white-board phase of development in 2015, Gilman says he was ripe for the challenge and adventure. And it’s a big one.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.